Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

BACKGROUND: Cisplatin is a first-line drug for the treatment of human non-small cell lung cancer (NSCLC); however, the majority of patients will develop drug resistance after treatment. In order to overcome cisplatin resistance, it is important to understand the mechanisms underlying the resistance....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Wang, Wenjing, Zhao, Mengyue, Cui, Lijuan, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Jia, Lina, Zhang, Jiayu, Yang, Jingyu, Chen, Guoliang, Ashby, Charles R., Wu, Chunfu, Chen, Zhe-Sheng, Wang, Lihui
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7466461/
https://ncbi.nlm.nih.gov/pubmed/32878625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01256-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados